6-Month clinical data abstract accepted for Poster Presentation at ICS 2018

14 August 2018

We are pleased to announce that our 6-month clinical data abstract has been accepted for Poster Presentation at the upcoming ICS 2018 Meeting 28-31 August in Philadelphia, USA.

CONCLUDING MESSAGE:

QoL measures are an essential end-point for measuring patients perceptions of the effects of incontinence treatments. Improvements in QoL shown here further demonstrate the efficacy of this PCL-based bulking agent. In addition to its efficacy, bioresorption is an attractive safety feature of the PCL-based bulking agent when compared to permanent materials. Preliminary results suggest that the bioresorbable PCL-based bulking agent is a promising safe and effective treatment option, and a valuable addition to the current treatment armament for female patients with mild to moderate SUI, who attempted and failed prior pelvic floor muscle training.

Please click here to read the full abstract.

Please click here to download the ePoster.